Centre for Reproductive Medicine, Women and Children's Hospital, Qingdao University, Qingdao, 266011, China.
Branch of Shandong Provincial Clinical Research Center for Reproductive Health, Qingdao, 266011, China.
Small. 2024 Nov;20(47):e2403890. doi: 10.1002/smll.202403890. Epub 2024 Aug 29.
Platelet-rich plasma (PRP) intrauterine infusion has been demonstrated to be effective in treating thin endometrium and achieving pregnancy. However, the rapid release of growth factors limits its effectiveness in clinical applications, and thus, multiple intrauterine infusions are often required to achieve therapeutic efficacy. In this study, a GelMA hydrogel microsphere biomaterial is developed using droplet microfluidics to modify the delivery mode of PRP and thus prolong its duration of action. Its biocompatibility is confirmed through both in vivo and in vitro studies. Cell experiments show that PRP-loaded microspheres significantly enhance cell proliferation, migration, and angiogenesis. In vivo experiments show that the effects of PRP-loaded microspheres on repairing the endometrium and restoring fertility in mice could achieve the impact of triple PRP intrauterine infusions. Further mechanistic investigations reveal that PRP could facilitate endometrial repair by regulating the expression of E2Fs, a group of transcription factors. This study demonstrates that hydrogel microspheres could modify the delivery of PRP and prolong its duration of action, enabling endometrial repair and functional reconstruction. This design avoids repeated intrauterine injections of PRP in the clinic, reduces the number of patient visits, and provides a new avenue for clinical treatment of thin endometrium.
富血小板血浆(PRP)宫腔内灌注已被证明可有效治疗薄型子宫内膜并实现妊娠。然而,生长因子的快速释放限制了其在临床应用中的效果,因此,通常需要多次宫腔内灌注以达到治疗效果。在这项研究中,使用液滴微流控技术开发了一种 GelMA 水凝胶微球生物材料,以改变 PRP 的递送方式,从而延长其作用时间。通过体内和体外研究证实了其生物相容性。细胞实验表明,负载 PRP 的微球显著促进了细胞增殖、迁移和血管生成。体内实验表明,负载 PRP 的微球在修复子宫内膜和恢复小鼠生育能力方面的效果可达到三重 PRP 宫腔内灌注的影响。进一步的机制研究表明,PRP 可以通过调节 E2Fs(一组转录因子)的表达来促进子宫内膜修复。这项研究表明,水凝胶微球可以改变 PRP 的递送方式并延长其作用时间,从而实现子宫内膜修复和功能重建。这种设计避免了临床上重复进行 PRP 宫腔内注射,减少了患者就诊次数,为薄型子宫内膜的临床治疗提供了新途径。